key: cord-0753222-hei40vv3
authors: Krzywański, Jarosław; Mikulski, Tomasz; Krysztofiak, Hubert; Pokrywka, Andrzej; Młyńczak, Marcel; Małek, Łukasz A.; Kwiatkowska, Dorota; Kuchar, Ernest
title: Elite athletes with COVID-19 – predictors of the course of disease
date: 2021-07-14
journal: J Sci Med Sport
DOI: 10.1016/j.jsams.2021.07.003
sha: 5f0848ca2867fc12bfe611a9c6cecb087cd60bdc
doc_id: 753222
cord_uid: hei40vv3

OBJECTIVES: The aim of the study was to identify predictors determining the course of COVID-19 and antibody response in elite athletes. DESIGN: Observational study. METHODS: Routine medical screening with physical examination, resting ECG, and laboratory tests including antibody response was performed 12-68 days after the diagnosis of COVID-19 in 111 athletes of different sports. RESULTS: Clinical symptoms were observed in 84% of subjects. The severity of COVID-19 was mild in 82% of athletes and moderate in 2% of cases. Athletes aged above 26 and male were more likely to develop symptomatic COVID-19. Asymptomatic subjects were younger and predominantly female. In 18% of subjects, symptoms were still present 20 (12-68) days (median and range) since positive diagnosis. Antibody response was observed in 88% of athletes, and its magnitude correlated with time since diagnosis of COVID-19 (RT-PCR), fatigue, fever, and conjunctivitis. There were no differences in antibody response between groups distinguished by sports discipline (p=0.50), and sex (p=0.59), and antibody response did not correlate with BMI (p=0.12), age (p=0.13), the number of symptoms (p=0.43) or their duration (p=0.19). CONCLUSIONS: The severity of COVID-19 in elite athletes is predominantly mild and without complications. Athletes can return to sport after two symptom-free weeks and additional heart screening is usually not required. Determination of antibodies has been shown to be a useful indicator of a previous COVID-19 disease, and some symptoms can be used as predictors of antibody response.

The Coronavirus Disease 2019 (COVID- 19) pandemic has introduced enormous changes in human existence, including sport. Many postponed or canceled events, limited access to training facilities, and sanitary restrictions have negatively impacted athletes' lives. 1 Additionally, the threat of unpredictable health issues after the COVID-19 has emerged, and arose the question, how to return to sport safely.

The clinical course and consequences of COVID-19 in non-athletic populations have already been explored and depend mostly on the presence of comorbidities and age. 2, 3 The infection could be asymptomatic, but most frequently, in over 80% of patients, the clinical course is mild. 4 There are limited data on COVID-19 clinical symptoms, complications, and antibody response in physically active people, especially elite athletes. In this group, the primary health concern is myocarditis since SARS-CoV-2 demonstrates a cardiac tropism by directly influencing cardiomyocytes and endothelial cells or indirectly by systemic inflammation via increased cytokines activity. 5 The current position papers on the return to play consider those risks but recommend monitoring and returning to sports activity within two symptom-free weeks depending on disease severity. 6-10 The guidelines mentioned above are based on experts' opinion since the published evidence on the COVID-19 clinical course, consequences, and antibody response in athletes are scanty.

The aim of the study was to identify predictors determining the course of COVID-19 and antibody response in elite athletes.

were Caucasians and represented different sport categories: strength (wrestling, judo, track and field sprinting and throwing), endurance (middle distance running, cycling, speed skating, cross country skiing, swimming), team sports (handball, beach volleyball), and technical disciplines (fencing, curling).

Baseline characteristics are presented in Table 1 . Medical screening was performed on a voluntary basis 20 (12-68) days (median and range) after diagnosis of COVID-19 and included detailed physical examination, resting ECG, and laboratory tests, including whole blood count, markers of inflammation (C-reactive protein -CRP) and cardiac injury (high-sensitive troponin T) using standardized equipment (Cobas 800, Roche, Rotkreuz, Switzerland). The following cut-off values were applied: leukopenia <4000/µl, neutropenia <2000/µl, leukocytosis >10000/µl, CRP <5 mg/l, hs-troponin T <0.014 ng/ml.

For the detection of SARS-CoV-2 seropositivity, the qualitative immunoassay for the detection of antibodies (including IgG) to SARS-CoV-2 in human serum (Elecsys® Anty-SARS-CoV-2 assay), and Cobas e411 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) were used.

SARS-CoV-2 nucleocapsid antigen is detected with an electrochemiluminescence sandwich assay (ECLIA). Results are semi-quantitative and are expressed as qualitative statements (reactive or nonreactive) and in the form of a Cut-off-Index (COI) interpreted as follows: COI ≥ 1 is considered positive, while a COI < 1 is negative. 11 The COI is a numerical representation of the measured fluorescence signal, and the COI values are approximately proportional to the concentration of the IgM and IgG antibodies in the specimen. This antibody assay has also received emergency use authorization from the US Food and Drug Administration for the detection of total antibodies (IgG, IgM, and IgA) in COVID-19 infected patients. 12 The concentration of 25(OH)D, a marker of vitamin D status, was determined with Liaison diagnostic system (DiaSorin, USA) by a chemiluminescent immunoassay (38%), congestion or rhinorrhea 30 (27%), cough 29 (26%), sore throat 22 (20%), fever 21 (19%), dyspnea 19 (17%), chills 19 (17%), gastrointestinal discomfort 11 (10%), conjunctivitis 10 (9%) and hemoptysis 1 (1%).

Asymptomatic subjects were younger (18.5±2.1 vs. 23.2±5.6 yrs., p<0.001) and more often female (23.7% female vs. 7.7% male, p<0.05). The relationship between the proportion of symptoms and age was shown to be significant at an age cutoff of 26 years.

At the medical screening, 20 subjects (18%) still reported abnormal symptoms, among whom in 9 (8%) additional diagnostic tests were performed: cardiac Magnetic Resonance (MR) due to exertional dyspnea, chest pain, and elevated hs-troponin T, and chest CT due to dyspnea in and hemoptysis.

The cardiac MR scans identified no cases of active myocarditis or pericarditis. There were also no signs of fibrosis suggesting prior myocarditis or structural heart diseases.

In one subject, the chest CT scans revealed pneumonia 20 days since the positive RT-PCR, whereas in others the CT scans were normal. The subjects presenting symptoms at the screening time were older At the time of medical screening (median 20 days since COVID-19 was diagnosed), the subjective feeling of decreased exercise tolerance was reported by three subjects (3%). Furthermore, symptoms as olfactory or gustatory dysfunction were reported in 7 subjects (6%) and headache during exercise in 1 subject (1%).

Abnormal blood test results were observed in 12 athletes (11%). In 10 cases (9%), the white blood cell count was abnormal (8 patients had leukopenia (range 2900-3900/µl) with neutropenia (range 1100-1900/µl), 1 patient had leukopenia only (3700/µl), 1 patient had leukocytosis (12000/µl)), 1 patient had Elevated hs-troponin T was found in one judoka, but myocarditis and other structural heart were excluded in cardiac MR. In the aforementioned studies by both Rajpal et al. and Clark et al., no athlete had elevated troponin T serum levels. 19, 21 Recent study on soccer players demonstrated that mild elevation of cardiac troponin was occasionally observed irrespectively of positive results of SARS-CoV-2 test, as troponin has been shown to transiently raise in response to repeated, especially intensive, exercise and training. 32 No diagnostic ST/T wave changes on electrocardiogram were found in the present study, which is consistent with the results of both Rajpal et al. and Clark et al. 19, 21 Vitamin D is involved in immunomodulation. Several authors have found it beneficial for the incidence and severity of COVID-19. 36 That effect is usually described in older and more severely symptomatic subjects. In the present study, no relationship was found between vitamin D status and COI or severity of COVID-19, probably because athletes were young, otherwise healthy, and experienced COVID-19 mildly.

It is identified that after 14 days since the onset of COVID-19 symptoms, antibodies directed against SARS-CoV-2 can be detected in over 90% of subjects, and they are recognized as an essential predictor of population immunity. 37 The antibody kinetics varied across the severity gradient with longer durations of detectable antibodies associated with more severe symptoms. 38 The prevalence of the antibody positivity against SARS-CoV-2 remains unknown in the athletic population. During 9 weeks of the study by Schumacher et al. positive serology was found in 42% of 36 infected soccer players. 20 In the present study, antibody response (COI>1) was observed in 88% of athletes with COVID-19, which proves its reliability in evaluating seroprevalence. Moreover, it was confirmed that the COI is time-dependent. The COI was not different between symptomatic and asymptomatic subjects, but fatigue was reported less frequently by athletes with low antibody levels. Interestingly, fatigue, fever, and conjunctivitis correlated with COI. The next months will be critical to evaluate the robustness of the immune response to SARS- The study has some limitations. It is retrospective, observational, and without a non-athletic control; the time of examination since diagnosis is long and not unified (median 20, range 12-68 days). The number of athletes representing different sport disciplines is not similar.

The course of COVID-19 in elite athletes is predominantly mild and without complications. Male athletes aged above 26 are more likely to develop symptomatic COVID-19, whereas younger females are more frequently asymptomatic. Usually, additional heart screening is not required, and athletes can return to play after two asymptomatic weeks. Determination of antibodies has proved to be a useful indicator of past infection of SARS-CoV-2, and should help build the protection strategy before the major sports events during the COVID-19 pandemic.

This research did not receive any specific funding.

Declarations of interest: none. 

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

Cardiorespiratory considerations for return-to-play in elite athletes after COVID-19 infection: a practical guide for sport and exercise medicine physicians

A game plan for the resumption of sport and exercise after coronavirus disease 2019 (COVID-19) infection

The Australian Institute of Sport framework for rebooting sport in a COVID-19 environment

Return to sports after COVID-19 infection

Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer

Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays

Position statement. Part one: immune function and exercise

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Asymptomatic and presymptomatic SARSCoV-2 infections in residents of a long-term care skilled nursing facility-King County

Clinical characteristics of 3062 COVID-19 patients: a meta-analysis

Social distancing alters the clinical course of COVID-19 in young adults: a comparative cohort study

Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection

COVID-19 myocardial pathology evaluated through screening cardiac magnetic resonance (COMPETE CMR)

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Age and T-cell repertoire

SARS-CoV-2 infections in children and young people

Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area

Sex differences in immune responses that underlie COVID-19 disease outcomes

Immune determinants of COVID-19 disease presentation and severity

Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis

Cardiac involvement in consecutive elite athletes recovered from Covid-19: a magnetic resonance study

SARS-CoV-2 Cardiac Involvement in Young Competitive Athletes

Interpretation of elevated high-sensitivity cardiac troponin I in elite soccer players previously infected by severe acute respiratory syndrome coronavirus 2

Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): A pooled analysis and review

Laboratory findings of COVID-19 infection are conflicting in different age groups and pregnant women: a literature review

Coronavirus disease (COVID-19) and neonate: What neonatologist need to know

Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19?

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

No financial assistance and grant support have been provided for this project.Authors dedicate special thanks to other contributors of the study: Alicja Felkner, Agnieszka Pietrak, Ewa Stasiakowska-Grochowska, Pawel Kaliszewski and Paulina Siek.